Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DRAK2 CRISPR/Cas9 KO Plasmid (h): sc-404787
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DRAK2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DRAK2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DRAK2 Antibody (C-2): sc-398324
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DRAK2 CRISPR/Cas9 KO Plasmid (h) | sc-404787 | 20 µg | $397.00 |
Overview
STK17B encodes DRAK2, a serine/threonine kinase of the death-associated protein kinase family that modulates signaling thresholds in immune cells. DRAK2 is linked to regulation of T cell receptor–dependent activation, Ca2+ signaling dynamics, and downstream transcriptional programs that shape proliferation, cytokine responses, and survival. Through these functions, it contributes to control of apoptosis and cellular stress responses, integrating with pathways that influence immune homeostasis and inflammation. Altered STK17B activity or expression has been associated with immune dysregulation and inflammatory disease contexts, making it a useful node for mechanistic studies in leukocyte biology.
DRAK2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the STK17B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the STK17B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the STK17B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DRAK2 protein expression.
This CRISPR knockout system enables efficient generation of STK17B-deficient cell models for investigation of DRAK2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting STK17B exon(s) critical for DRAK2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple STK17B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by DRAK2 CRISPR/Cas9 KO Plasmid (h) and DRAK2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the STK17B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by DRAK2 HDR Plasmid (h) and DRAK2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by STK17B homology arms to support homology-directed repair at defined STK17B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.